Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
This is GREAT news! Thanks for posting.... Also the board is amazing!
How so?
Ha! Again my smiley face has turned into a question mark....
Enjoy the weekend all!
Well said Bio! Have an awesome 4th of July weekend everyone ???? Our investment here does not depend upon message boards, stock traders, or even press releases good or bad... We have the most respected physicians involved in bringing our delivery system to the world and when that happens we will be rewarded in share increase. It must be exhausting to nitpick pennies and post multiple negative comments on message boards 24/7 to try and make a few bucks.... Each to his/her own I suppose! I believe PMCB has the goods so I can rest and patiently wait for the one PR that will make the difference!
Love this stock, no one talks about it though lol...
COMPLETE TUMOR REMISSION!!!!
That is a whole lot of "Going on" lol!
"Complete Tumor Remission"
Let's not forget this!
Very excited about the future of PMCB!
You also should view this!
$PMCB PharmaCyte Biotech Corporate Video – June 1, 2015
Have you not viewed the video?
$PMCB PharmaCyte Biotech Corporate Video – June 1, 2015
What a fantastic company! I just watched the video and was just blown away by the incredible presentation of what most of us here knew was happening anyway.... A clear path to success on so many levels I can't believe this share price! Phenomenal opportunity here to get in on something big!
love your take on this! Curing disease puts pharma out of business essentially... so much corruption between govt. & lobbyists! We need leaders with integrity to focus on what is best for people, not their own lust for power...
PMCB has such people in their company and on their research teams! Good will ALWAYS triumph over evil.... Always!
Yes! VERY GOOD NEWS!
Know what you are holding....
http://finance.yahoo.com/news/pharmacyte-biotechs-melligen-cells-prove-133000003.html
Exciting days ahead for PMCB and this technology!
5! woohoo! Ready for breakthrough now ...
Looking forward to an outstanding May with this outstanding company! Go PMCB!
Excited about the future which is indeed looking brighter for many because of PMCB!
Keep on with your DD & you will see what many of us do here... Patience will reward us!
PMCB is doing what it takes to succeed one day at a time...
The value proposition provided PharmaCyte Biotech in the Consortium’s efforts is clear and a higher valuation should be afforded the Company each time a key research stage is completed, which should occur in the coming quarters, and as outlined above.
http://www.goldmanresearch.com/20150428977/Opportunity-Research/unprecedented-diabetes-research-collaboration-to-lead-to-expedited-pharmacyte-biotech-clinical-trials.html
No worries on my investment here!
In my opinion if you have done DD on Pharmacyte and are invested here because you believe in their future success it doesn't really matter what the pps or chart looks like right now. This stock is heavily played by day traders, shorts etc.... Soon though when great results are released from current trials they will need to move on to another penny victim. GO PMCB!
How can this be legal?
Wish they would pump it enough to where I get my money back lol
I really, really love this company.... It just keeps getting better everyday! There is no rational reason to be anxious over the profit takings by a few penny traders! Keep your eye on the real prize PMCB investors...$$$$$ Hold tight to your shares
PharmaCyte Biotech Finalizes International Diabetes Consortium to Cure Diabetes - See more at: http://globenewswire.com/news-release/2015/04/20/726072/10129577/en/PharmaCyte-Biotech-Finalizes-International-Diabetes-Consortium-to-Cure-Diabetes.html?parent=719662#sthash.5B9v1BzJ.dpuf
What is the connection to GERN? If anyone cares to share info on AST I would be much appreciative! I was gifted some shares but not quite sure why...
Love this company! PMCB is a great investment.... Soon imo the world will see it as well & those here fortunate enough to know what we hold and those who are new & have not been scared off by the penny traders and their game will be rewarded for their patience!
When it goes to 1.27 maybe I can get excited.... Been here for awhile and have have heard this before... Just curious, one else here that was burned on the last run with high expectations?
Yes, I agree.....the current regime will be soon history & when that happens lbsr will be released to get this moving in my opinion.
Very happy with the progress so far! Go pharmacyte your investors, researchers and management all believe success to ciab delivery system sooner rather than later in mho
Well said! Success in the labs is why many of us are invested in PMCB. We believe when trials prove the technology is successful, shareholders will be rewarded. I realize there are also traders who don't much care whether the company or research succeeds or fails as long as they "play" it right... to each their own! Go PMCB!
There are those on this PMCB board with obvious conflicts of interests to put it mildly! If you are new, please research for yourself!
http://www.pharmacytebiotech.com/pharmacyte-biotech-provides-update-on-corporate-developments-and-progress-with-cancer-and-diabetes-programs/
SILVER SPRING, Md., March 16, 2015 (GLOBE NEWSWIRE) — PharmaCyte Biotech, Inc. (PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box(R), today provided shareholders with an update on developments on progress in its cancer and diabetes programs and at the corporate level.
SILVER SPRING, Md., March 16, 2015 (GLOBE NEWSWIRE) — PharmaCyte Biotech, Inc. (PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box(R), today provided shareholders with an update on developments on progress in its cancer and diabetes programs and at the corporate level.
http://www.pharmacytebiotech.com/pharmacyte-biotech-provides-update-on-corporate-developments-and-progress-with-cancer-and-diabetes-programs/
Wrong:
SILVER SPRING, Md., March 16, 2015 (GLOBE NEWSWIRE) — PharmaCyte Biotech, Inc. (PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box(R), today provided shareholders with an update on developments on progress in its cancer and diabetes programs and at the corporate level.
Beautiful! Loved watching this video, it shows the dedication and compassion he has for people in desperate situations. May success come sooner rather than later for our trials! EQUITY!
Go PMCB!
The Von Hoff Factor
Last May PMCB delivered a major breakthrough. Translational Drug Development of Arizona agreed to conduct preclinical and clinical trials.
The gentleman you see pictured here is the head of Translational Drug- Dr. Daniel Von Hoff. His company has spent the last 2 decades developing cancer drugs. He was on President Bush's National Cancer Society Board, the FDA's oncology Advisory Committee, and is the former President of the American Association for Cancer Research.
Under Von Hoff's direction, the first preliminary studies have been concluded, and the clinical protocol for the Phase 2B trial has been developed. The next step is planning the commencement of the trial with the FDA and other similar agencies Internationally.
On December 22 PMCB announced its Pancreatic Cancer Therapy had received "Orphan Drug Status" from the US FDA- a huge coup. Thanks to the proximity to Christmas, the announcement did not receive proper recognition. To see the evidence on the FDA web site, simply Click Here.
Orphan Drug status is reserved for drugs or treatments for "rare, life threatening diseases." Once approved, PMCB will own the drug exclusively for 7 years.
That's a good question, however I won't pretend to be qualified to answer :) Success in these trials will bring a nice increase to shareholders whichever way management decides to go With it!
Thank you Wendy, I will remember that :)
It's so exciting all the things that are taking place here!!
Go PMCB!
Ok, my smiley face was changed to a question mark!
Awesome news, love my investment here ??
Go PMCB!
PharmaCyte Biotech Provides Update on Corporate Developments and Progress With Cancer and Diabetes Programs
Source: GlobeNewswire Inc.
PharmaCyte Biotech, Inc. (OTCQB:PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, today provided shareholders with an update on developments on progress in its cancer and diabetes programs and at the corporate level.
Kenneth L. Waggoner, Chief Executive Officer of PharmaCyte Biotech, stated, "Given all of the developments that have occurred since our last update, we believe it is an appropriate time to update our shareholders on developments and to highlight and briefly summarize what is in store for PharmaCyte Biotech in the coming days. Before doing so, however, we would like to address two issues that reportedly are of significant concern to a number of our shareholders. The first has to do with whether a reverse stock split is imminent. The second is whether we have access to capital to move forward with our clinical trials. PharmaCyte Biotech has no current plans to effectuate a reverse stock split. In addition, our cash position remains strong and our ability to raise capital continues to be very favorable."
"As to the update, we remain focused on bringing our diverse platform technology to market and firmly believe our novel Cell-in-a-Box-based treatment will become a household name in the future. Our priority is and always has been to maximize shareholder value, and we are working diligently to reach that objective," added Mr. Waggoner.
Progress in the Cancer Program
PharmaCyte Biotech's treatment (Cell-in-a-Box® plus low-doses of ifosfamide) for advanced, inoperable pancreatic cancer was granted the Orphan Drug designation by the U.S. Food and Drug Administration (FDA) in late December of 2014.
On the basis of very positive results from our first preclinical study (4 groups of tumor bearing mice) that was conducted by Translational Drug Development (TD2) in the U.S. to determine the ability of the Cell-in-a-Box® plus low-doses of ifosfamide combination to delay the accumulation of malignant ascites fluid produced by abdominal cancers, an expanded study (12 groups of mice) is currently being conducted by TD2. This study is designed to elucidate parameters that will be needed for a future clinical trial that may result in the only treatment that can slow down the accumulation of malignant ascites fluid. It is expected that the study will be completed in the next 2 months. The target date for the initiation of the Phase 1 clinical trial in the U.S. is the third quarter of 2015.
Preparations for the Phase 2b clinical trial in patients with advanced, inoperable pancreatic cancer are ongoing. Major documents, including the Investigators Brochure and a clinical protocol (a recipe for conducting the clinical trial) are in preparation, with the assistance of Clinical Network Services (CNS) - one of Australia's leading Clinical Research Organizations. The target date for the initiation of the Phase 2b clinical trial in Australia is the third quarter of 2015.
We initially reported that we expected to begin our Phase 2b clinical trial in the first quarter of 2015; however, we are awaiting the Good Manufacturing Practices (GMP) regulatory approval process that our partner, Austrianova, is currently involved with in order to get the GMP-compliant facility at the Thai Science Park in Bangkok, Thailand, approved to produce Cell-in-a-Box® capsules for human clinical trials. Austrianova believes the process will now be completed in the third quarter of 2015.
Progress is ongoing at the University of Northern Colorado in an attempt to identify a cell line that can be encapsulated using the Cell-in-a-Box® technology, which, in turn, can be used together with cannabinoid or cannabinoid-like prodrugs as a treatment for deadly cancers - such as brain and pancreatic cancer.
Progress in the Diabetes Program
Studies are in progress at the University of Veterinary Medicine, Vienna (UVM) to determine if Melligen (human, non-pancreatic, insulin-producing) cells are tumorigenic and to establish parameters by which these cells (human, non-pancreatic, insulin-producing) can produce and store insulin in response to glucose levels in their surroundings. The coordinator for these studies is Dr. Constantine Konstantoulas of UVM.
An exclusive license to use the Melligen cells developed by Prof. Ann Simpson of the University of Technology Sydney (UTS) in Australia has been obtained from UTS by PharmaCyte Biotech from UTS.
Dr. Eva-Maria Brandtner has been appointed Director of the Diabetes Research Program. Dr. Brandtner, presently at the Vorarlberg Institute for Vascular Investigation and Treatment (VIVIT) in Austria, was responsible for studies with the Melligen cells during her previous tenure with our partner, Austrianova, at its Chief Scientist.
Developments at the Corporate Level
The Company changed its name from Nuvilex, Inc. to PharmaCyte Biotech, Inc. to emphasize that it has fully transitioned from a nutraceutical company to a purely biotechnology company.
Changes have been and are being made at the Board of Directors level, with additional member candidates to the Board in their final interview process; these new members will be widely experienced in the life sciences.
Waggoner concluded, "We are pleased to offer this update to our shareholders. We trust that they will agree that significant progress is being made on all fronts."
About PharmaCyte Biotech
PharmaCyte Biotech is a clinical stage biotechnology company focused on developing and preparing to commercialize treatments for cancer and diabetes based upon a proprietary cellulose-based live cell encapsulation technology known as Cell-in-a-Box®. This unique and patented technology will be used as a platform upon which treatments for several types of cancer, including advanced, inoperable pancreatic cancer, and diabetes are being built. PharmaCyte Biotech's treatment for pancreatic cancer involves low doses of the well-known anticancer prodrug ifosfamide, together with encapsulated live cells, which convert ifosfamide into its active or "cancer-killing" form. These capsules are placed as close to the cancerous tumor as possible to enable the delivery of the highest levels of the cancer-killing drug at the source of the cancer. This "targeted chemotherapy" has proven remarkably effective in past clinical trials. PharmaCyte Biotech is also working towards improving the quality of life for patients with advanced pancreatic cancer and on treatments for other types of solid cancerous tumors. In addition, PharmaCyte Biotech is developing treatments for cancer based upon chemical constituents of the Cannabis plant, known as cannabinoids. In doing so, PharmaCyte Biotech is examining ways to exploit the benefits of Cell-in-a-Box® technology in optimizing the anticancer effectiveness of cannabinoids, while minimizing or outright eliminating the debilitating side effects usually associated with cancer treatments. This provides PharmaCyte Biotech the rare opportunity to develop "green" approaches to fighting deadly diseases, such as cancer of the pancreas, brain and breast, which affect hundreds of thousands of individuals worldwide every year.
Safe Harbor
This press release may contain forward-looking statements regarding PharmaCyte Biotech and its future events and results that involve inherent risks and uncertainties. The words "anticipate," "believe," "estimate," "expect," "intend," "plan" and similar expressions, as they relate to PharmaCyte Biotech or its management, are intended to identify forward-looking statements. Important factors, many of which are beyond the control of PharmaCyte Biotech, could cause actual results to differ materially from those set forth in the forward-looking statements. They include PharmaCyte's ability to continue as a going concern, delays or unsuccessful results in preclinical and clinical trials, flaws or defects regarding its product candidates, changes in relevant legislation or regulatory requirements, uncertainty of protection of PharmaCyte Biotech's intellectual property and PharmaCyte Biotech's continued ability to raise capital. PharmaCyte Biotech does not assume any obligation to update any of these forward-looking statements.
More information about PharmaCyte Biotech can be found at www.PharmaCyteBiotech.com. It can also be obtained by contacting Investor Relations.
CONTACT: Investor Relations Contacts:
Jamien Jones
Blueprint Life Science Group
Telephone: 415.375.3340 Ext. 103
jjones@bplifescience.com
What the share price is today, this moment means nothing to investors who know what they hold...
Below is more good reading while we wait for success;
http://marijuanastocks.com/pmcb-partner-austrianova-opens-new-facilities-singapore/